InvestorsHub Logo

orangecat

09/10/18 9:45 AM

#13179 RE: orangecat #13178

I looked at the authors other articles and just 5 days ago she published one on CAR T-Cell therapy. How in the world could someone aware of CAR T write an article on Cytosorb and not note the fact that both CAR T and Cytosorb are approved in Europe and Cytosob is a possible treatment for the most serious side effect of CAR T?

kjpcrna

09/10/18 2:42 PM

#13181 RE: orangecat #13178

I thought the article was pretty good; short and to the point. It’s aimed at the general public, not folks with a financial or humanitarian interest who follow the companies stock. She’s a writer, not a PR person. Was also glad to see reference to Cleveland Clinic staff awareness, mention of $20 billion potential market just to name two positives. I’ve invested an absurd amount of money in this stock and no one wants it to succeed more than me, but at this point I’ll take any positive press from an outside source.